The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
Kyowa Kirin’s group sales rose 12.3% from a year ago in the first six months of 2022 propped up by the robust growth of its global strategic products in North America and EMEA, which more than countered the sluggish performance…
To read the full story
Related Article
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…